Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2013 May 10;31(14):1709-12.
doi: 10.1200/JCO.2013.48.8825. Epub 2013 Apr 8.

Phase III trials with docetaxel-based combinations for metastatic castration-resistant prostate cancer: time to learn from past experiences

Emmanuel S Antonarakis, Mario A Eisenberger
Editorial

Phase III trials with docetaxel-based combinations for metastatic castration-resistant prostate cancer: time to learn from past experiences

Emmanuel S Antonarakis et al. J Clin Oncol. .
No abstract available

PubMed Disclaimer

Comment on

References

    1. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–1512. - PubMed
    1. Antonarakis ES, Eisenberger MA. Expanding treatment options for meta-static prostate cancer. N Engl J Med. 2011;364:2055–2058. - PMC - PubMed
    1. Fizazi KS, Higano CS, Nelson JB, et al. Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2013;31:1740–1747. - PubMed
    1. Trump DL, Payne H, Miller K, et al. Preliminary study of the specific endothelin A receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancer. Prostate. 2011;71:1264–1275. - PubMed
    1. James ND, Caty A, Payne H, et al. Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: A double-blind, placebo-controlled, randomized phase II trial. BJU Int. 2010;106:966–973. - PubMed

MeSH terms